Most Recent
Judge rejects ‘fishing expedition’ in prospective suit over DNA sequencing patents
Intellectual Property 2025-06-04 11:09 pm By Sam Matthews

A judge has thrown out a notice to produce issued by an Australian company being targeted by UK genomic sequencing company Oxford Nanopore Technologies, calling its bid for board minutes and other documents a “fishing expedition”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Apple defeats patent infringement suit over Touch ID technology
Intellectual Property 2025-05-15 3:32 pm By Cindy Cameronne

Apple has defeated a claim by an Australian non-practicing entity that its patents for a remote entry system were infringed by the tech company’s Touch ID and Face ID technology. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Momofuku restaurant loses challenge to instant Ramen maker’s trade mark
Intellectual Property 2025-05-06 11:19 pm By Sam Matthews

Famed restaurant chain Momofuku has lost its challenge to the ‘Momofuku’ word mark of instant noodle giant Nissin, with IP Australia finding consumers were not likely to be deceived or confused because of the different goods and services provided by the two companies.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Further or in the alternative’ no problem in bovine gene patent suit: court
Intellectual Property 2025-04-08 11:23 pm By Sam Matthews

A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Lundbeck, Sandoz end long-running Lexapro patent war
Intellectual Property 2025-02-27 11:06 pm By Christine Caulfield

Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pilatus wins discovery for potential IP suit linked to Air Force contract
Intellectual Property 2025-01-21 11:21 pm By Andy Sidler

Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Hytera launches High Court challenge in IP dispute with Motorola
Intellectual Property 2025-01-17 3:39 pm By Cindy Cameronne

Radio manufacturer Hytera wants the High Court to hear its appeal of a finding that it misappropriated Motorola’s source code in a case of “substantial industrial theft”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Hytera can’t dodge ‘substantial industrial theft’ finding in Motorola case
Intellectual Property 2024-12-18 3:28 pm By Sam Matthews

An appeals court has rejected Chinese radio manufacturer Hytera’s challenge to a finding it misappropriated the source code of US mobile phone giant Motorola.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Cipla loses bid to cut short Novo Nordisk’s weight loss drug patent
Intellectual Property 2024-12-13 11:11 pm By Sam Matthews

Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Intellectual Property 2024-11-22 2:45 pm By Sam Matthews

As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?